Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026
Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026
Company Drug

Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study

Fineline Cube Mar 6, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...

Company Drug

Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars

Fineline Cube Mar 6, 2024

The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter

Fineline Cube Mar 6, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...

Company Drug

Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment

Fineline Cube Mar 6, 2024

Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Three Cancer Treatments Including a Novel ADC

Fineline Cube Mar 6, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, has received separate clinical trial approvals...

Policy / Regulatory

China’s Government Work Report Highlights Biomedicine Innovation and Healthcare Reforms

Fineline Cube Mar 5, 2024

Chinese Premier Li Qiang presented a concise Government Work Report at the Second Session of...

Company Drug

EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications

Fineline Cube Mar 5, 2024

The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...

Company Drug

Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis

Fineline Cube Mar 5, 2024

The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points...

Policy / Regulatory

China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024

Fineline Cube Mar 5, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three...

Company Drug

Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group

Fineline Cube Mar 5, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...

Company Deals

Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases

Fineline Cube Mar 5, 2024

California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...

Company Drug

Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer

Fineline Cube Mar 5, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...

Company

Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management

Fineline Cube Mar 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...

Company Deals

Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics

Fineline Cube Mar 5, 2024

Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore...

Company Drug

Aosaikang’s Marketing Approval Filing for Delafloxacin Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...

Company Deals

Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion

Fineline Cube Mar 5, 2024

Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and...

Company Drug

Huadong Medicine’s Arcalyst Filing for Recurrent Pericarditis Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Huadong Medicine Co., Ltd, (SHE: 000963) a Chinese pharmaceutical company, has announced that the National...

Company Medical Device

Sino Medical Sciences Receives Hong Kong Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Mar 5, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for KRAS G12C Inhibitor Clinical Trial in Advanced Solid Tumors

Fineline Cube Mar 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment

Fineline Cube Mar 5, 2024

HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...

Posts pagination

1 … 343 344 345 … 615

Recent updates

  • Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
  • J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
  • Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
  • FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.